{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:01Z","timestamp":1790842081260,"version":"4.1.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"s2","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,11,30]]},"abstract":"<jats:p>Recently, the Food and Drug Administration granted accelerated approvals for four exon skipping therapies \u2013Eteplirsen, Golodirsen, Viltolarsen, and Casimersen \u2013for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated variable and largely sub-therapeutic levels of restored dystrophin protein in DMD patients, limiting their clinical impact. To better understand variable protein expression and the behavior of truncated dystrophin protein in vivo, we assessed turnover dynamics of restored dystrophin and dystrophin glycoprotein complex (DGC) proteins in mdx mice after exon skipping therapy, compared to those dynamics in wild type mice, using a targeted, highly-reproducible and sensitive, in vivo stable isotope labeling mass spectrometry approach in multiple muscle tissues. Through statistical modeling, we found that restored dystrophin protein exhibited altered stability and slower turnover in treated mdx muscle compared with that in wild type muscle (\u223c44\u200ad vs. \u223c24\u200ad, respectively). Assessment of mRNA transcript stability (quantitative real-time PCR, droplet digital PCR) and dystrophin protein expression (capillary gel electrophoresis, immunofluorescence) support our dystrophin protein turnover measurements and modeling. Further, we assessed pathology-induced muscle fiber turnover through bromodeoxyuridine (BrdU) labeling to model dystrophin and DGC protein turnover in the context of persistent fiber degeneration. Our findings reveal sequestration of restored dystrophin protein after exon skipping therapy in mdx muscle leading to a significant extension of its half-life compared to the dynamics of full-length dystrophin in normal muscle. In contrast, DGC proteins show constant turnover attributable to myofiber degeneration and dysregulation of the extracellular matrix (ECM) in dystrophic muscle. Based on our results, we demonstrate the use of targeted mass spectrometry to evaluate the suitability and functionality of restored dystrophin isoforms in the context of disease and propose its use to optimize alternative gene correction strategies in development for DMD.<\/jats:p>","DOI":"10.3233\/jnd-210696","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T12:55:00Z","timestamp":1632488100000},"page":"S383-S402","source":"Crossref","is-referenced-by-count":24,"title":["Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy"],"prefix":"10.1177","volume":"8","author":[{"given":"James S.","family":"Novak","sequence":"first","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019sResearch Institute, Children\u2019s National Hospital, Washington, DC, USA"},{"name":"Department of Genomics and PrecisionMedicine, The George Washington University School of Medicine and Health Sciences, Washington DC, USA"},{"name":"Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Spathis","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh J.","family":"Dang","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY USA"},{"name":"Department of Health Sciences, Carleton University, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson A.","family":"Fiorillo","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019sResearch Institute, Children\u2019s National Hospital, Washington, DC, USA"},{"name":"Department of Genomics and PrecisionMedicine, The George Washington University School of Medicine and Health Sciences, Washington DC, USA"},{"name":"Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Hindupur","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019sResearch Institute, Children\u2019s National Hospital, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Tully","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019sResearch Institute, Children\u2019s National Hospital, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davi A.G.","family":"M\u00e1zala","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019sResearch Institute, Children\u2019s National Hospital, Washington, DC, USA"},{"name":"Department of Kinesiology, College of Health Professionals, Towson University, Towson, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Canessa","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Solid Biosciences Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence A.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019sResearch Institute, Children\u2019s National Hospital, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[{"name":"Department of Genomics and PrecisionMedicine, The George Washington University School of Medicine and Health Sciences, Washington DC, USA"},{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/JND-210696_ref1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"4825","key":"10.3233\/JND-210696_ref2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.3659917","article-title":"Conservation of the Duchenne muscular dystrophy gene in mice and humans","volume":"238","author":"Hoffman","year":"1987","journal-title":"Science"},{"key":"10.3233\/JND-210696_ref3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurevgenom-090314-025003","article-title":"The Pathogenesis and Therapy of Muscular Dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annual review of genomics and human genetics"},{"issue":"10119","key":"10.3233\/JND-210696_ref4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.3233\/JND-210696_ref5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","article-title":"Developing DMD therapeutics: A review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies","volume":"30","author":"Sheikh","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.3233\/JND-210696_ref6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11307-010-0376-z","article-title":"Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging","volume":"13","author":"Baudy","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"10.3233\/JND-210696_ref7","doi-asserted-by":"publisher","first-page":"402369","DOI":"10.1155\/2013\/402369","article-title":"Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy","volume":"2013","author":"Aoki","year":"2013","journal-title":"BioMed Research International"},{"issue":"89","key":"10.3233\/JND-210696_ref8","first-page":"233","article-title":"Orphan drug development in muscular dystrophy: Update on two large clinical trials of dystrophin rescue therapies","volume":"16","author":"Hoffman","year":"2013","journal-title":"Discovery Medicine"},{"issue":"6","key":"10.3233\/JND-210696_ref9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","article-title":"New developments in exon skipping and splice modulation therapies for neuromuscular diseases","volume":"14","author":"Touznik","year":"2014","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"24","key":"10.3233\/JND-210696_ref10","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.3233\/JND-210696_ref11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"issue":"21","key":"10.3233\/JND-210696_ref12","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JND-210696_ref13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4\u20142","article-title":"An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases","volume":"1828","author":"Rodrigues","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"24","key":"10.3233\/JND-210696_ref15","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1093\/hmg\/ddu366","article-title":"Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients","volume":"23","author":"Hathout","year":"2014","journal-title":"Human Molecular Genetics"},{"key":"10.3233\/JND-210696_ref16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12014-016-9109-x","article-title":"Clinical utility of serum biomarkers in Duchenne muscular dystrophy","volume":"13","author":"Hathout","year":"2016","journal-title":"Clin Proteomics"},{"issue":"2","key":"10.3233\/JND-210696_ref17","doi-asserted-by":"publisher","first-page":"e4437","DOI":"10.1002\/jms.4437","article-title":"Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM)","volume":"55","author":"Canessa","year":"2020","journal-title":"J Mass Spectrom"},{"issue":"5","key":"10.3233\/JND-210696_ref18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1074\/mcp.M112.023127","article-title":"Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse","volume":"12","author":"Rayavarapu","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.3233\/JND-210696_ref19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.toxrep.2015.05.008","article-title":"The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse","volume":"2","author":"Zhang","year":"2015","journal-title":"Toxicology reports"},{"key":"10.3233\/JND-210696_ref20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jprot.2013.10.029","article-title":"Technical considerations for large-scale parallel reaction monitoring analysis","volume":"100","author":"Gallien","year":"2014","journal-title":"J Proteomics"},{"issue":"4","key":"10.3233\/JND-210696_ref21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.3233\/JND-210696_ref22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jgm.838","article-title":"Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide","volume":"8","author":"Fletcher","year":"2006","journal-title":"The Journal of Gene Medicine"},{"issue":"15","key":"10.3233\/JND-210696_ref23","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","article-title":"Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle","volume":"12","author":"Gebski","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.3233\/JND-210696_ref24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1073\/pnas.011408598","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.3233\/JND-210696_ref25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000113005","article-title":"Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues","volume":"45","author":"Morcos","year":"2144","journal-title":"BioTechniques"},{"issue":"1","key":"10.3233\/JND-210696_ref26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41467-017-00924-7","article-title":"Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle","volume":"8","author":"Novak","year":"2017","journal-title":"Nature Communications"},{"key":"10.3233\/JND-210696_ref27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13395-015-0070-6","article-title":"Elusive sources of variability of dystrophin rescue by exon skipping","volume":"5","author":"Vila","year":"2015","journal-title":"Skeletal Muscle"},{"issue":"24","key":"10.3233\/JND-210696_ref28","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","article-title":"Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice","volume":"22","author":"Aoki","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"34","key":"10.3233\/JND-210696_ref29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1073\/pnas.1204638109","article-title":"Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery","volume":"109","author":"Aoki","year":"1376","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.3233\/JND-210696_ref30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1385\/1-59259-584-7:513","article-title":"Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels","volume":"112","author":"Jensen","year":"1999","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.3233\/JND-210696_ref31","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjugate chemistry"},{"issue":"5","key":"10.3233\/JND-210696_ref32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/nat.2014.0528","article-title":"Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides","volume":"25","author":"Burki","year":"2015","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.3233\/JND-210696_ref33","doi-asserted-by":"publisher","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","article-title":"Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy","volume":"9","author":"Hathout","year":"2019","journal-title":"Scientific Reports"},{"issue":"7","key":"10.3233\/JND-210696_ref34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.nmd.2014.03.012","article-title":"Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy","volume":"24","author":"Rouillon","year":"2014","journal-title":"Neuromuscular disorders: NMD"},{"key":"10.3233\/JND-210696_ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082696"},{"key":"10.3233\/JND-210696_ref36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135703"},{"key":"10.3233\/JND-210696_ref37","doi-asserted-by":"publisher","first-page":"8986.","DOI":"10.1038\/srep08986","article-title":"Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice","volume":"5","author":"Betts","year":"2015","journal-title":"Scientific Reports"},{"issue":"2","key":"10.3233\/JND-210696_ref38","doi-asserted-by":"publisher","first-page":"e31937","DOI":"10.1371\/journal.pone.0031937","article-title":"The effects of low levels of dystrophin on mouse muscle function and pathology","volume":"7","author":"van Putten","year":"2012","journal-title":"PloS one"},{"issue":"2","key":"10.3233\/JND-210696_ref39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cdd.2016.127","article-title":"Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy","volume":"24","author":"Vila","year":"2017","journal-title":"Cell Death Differ"},{"issue":"15","key":"10.3233\/JND-210696_ref40","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1093\/hmg\/ddr199","article-title":"Internal deletion compromises the stability of dystrophin","volume":"20","author":"Henderson","year":"2011","journal-title":"Human Molecular Genetics"},{"issue":"21","key":"10.3233\/JND-210696_ref41","doi-asserted-by":"publisher","first-page":"9632","DOI":"10.1073\/pnas.1001517107","article-title":"Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation","volume":"107","author":"Henderson","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.3233\/JND-210696_ref42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13395-015-0040-z","article-title":"In vitro stability of therapeutically relevant, internally truncated dystrophins","volume":"5","author":"McCourt","year":"2015","journal-title":"Skeletal Muscle"},{"issue":"1","key":"10.3233\/JND-210696_ref43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JND-180357","article-title":"Report of a TREAT-NMD\/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology","volume":"6","author":"Aartsma-Rus","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-210696_ref44","doi-asserted-by":"publisher","DOI":"10.4172\/1948-593X.S7-001"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:50Z","timestamp":1777506590000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210696"}},"subtitle":[],"editor":[{"given":"Jyoti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":43,"journal-issue":{"issue":"s2"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210696","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}